I
IDEAYA Biosciences
Biotech & Life Sciences · San Francisco, United States · Founded 2015 · IPO 2019
An oncology company, develops cancer therapeutics MoreLess
IDEAYA Biosciences is a precision medicine company specializing in oncology, dedicated to discovering and developing targeted therapeutics for specific patient populations identified through molecular diagnostics. The company integrates expertise in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from its therapies. IDEAYA operates in the biotechnology and pharmaceutical market, primarily serving healthcare providers and patients with specific cancer types. The business model revolves around research and development, clinical trials, and eventual commercialization of its therapeutic products. Revenue is generated through partnerships, licensing agreements, and sales of approved drugs. Keywords: oncology, precision medicine, targeted therapeutics, molecular diagnostics, translational biomarkers, small molecule drugs, cancer treatment, biotechnology, clinical trials, healthcare.
Company overview
IDEAYA Biosciences company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2015
- Headquarters
- San Francisco, United States
- Employees
- 261
- Open positions
- 22
- Dealroom signal
- 91.7
Valuation & funding
IDEAYA Biosciences funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $345M | $2.6B | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jul 2024 | $302M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Oct 2023 | $125M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Apr 2023 | $175M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Sep 2022 | $92M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Sep 2022 | Undisclosed | ↗ | ||
| POST IPO EQUITYOther financing | Jul 2021 | Undisclosed | — | ||
| IPOOther financing | May 2019 | Undisclosed | — | ||
| SERIES BOther financing | Mar 2018 | Canaan · Roche Venture Fund · WuXi Healthcare Ventures · Driehaus Capital Management | — | ||
| SERIES AOther financing | May 2016 | 5AM Ventures · Celgene · Bristol-Myers Squibb · Canaan | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $219M | 0% | −$155M | -70.7% |
| 2025 | $219M | +3024.4% | −$155M | -70.7% |
| 2024 | $7M | -70.1% | −$323M | -4616.3% |
| 2023 | $23M | -54.1% | −$130M | -557.7% |
| 2022 | $51M | +82.3% | −$63M | -122.7% |
| 2021 | $28M | +43% | −$50M | -179.9% |
| 2020 | $20M | — | −$35M | -180.9% |
Growth signals
IDEAYA Biosciences website traffic
Latest recorded traffic for IDEAYA Biosciences is 9K monthly website visits, down 40% over the last three months. IDEAYA Biosciences's team grew 16% over the past year.
Hiring
Open positions at IDEAYA Biosciences
Current openings linked to this company in Dealroom.
Comparisons
IDEAYA Biosciences compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
IDEAYA Biosciences's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where IDEAYA Biosciences has talent and traffic
team presence
In the news
Latest news about IDEAYA Biosciences
Recent press, funding announcements, and product moves mentioning IDEAYA Biosciences — open to read from the original sources.
Market sentiment
What the market is saying about IDEAYA Biosciences
An AI-synthesized read of the highest-engagement posts about IDEAYA Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See IDEAYA Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.